Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A gynaecological examination was performed because of vaginal bleeding in a 67-year-old woman who was admitted for dyspnoea and a painful cough. A tumour was detected in the vaginal wall that turned out to be a metastasis of a locally extensive and metastasised Grawitz tumour. In a 76-year-old woman who presented with vaginal bleeding, speculum examination revealed a polyp that protruded from the cervix. A non-Hodgkin lymphoma was demonstrated histopathologically. In both patients, the cervical smear showed Pap-I. Both patients were given palliative treatment. According to the guidelines, the policy of general practitioners and gynaecologists in cases of postmenopausal blood loss should be directed primarily at the exclusion of malignancy by means of transvaginal echoscopy. However, some abnormalities may then be missed. A complete gynaecological examination then becomes very important. Speculum examination forms an essential part of such a work-up.
 ...
PMID:[Two post-menopausal women with vaginal bleeding due to non-gynaecological malignancies]. 1635 18

Endobronchial metastases (EBM) from extrapulmonary malignant tumors are rare. The most common extrathoracic malignancies associated with EBM are breast, renal and colorectal carcinomas. In this study, we aimed to evaluate the clinical, radiographic and bronchoscopic aspects of patients with EBM who were diagnosed between 1992 and 2002. Data about patients' clinical conditions, symptoms, radiographic and endoscopic findings, and histopathological examination results were investigated. EBM was defined as bronchoscopically visible lesions histopathologically identical to the primary tumor in patients with extrapulmonary malignancies. We found 15 cases with EBM. Primary tumors included breast (3), colorectal (3), and renal (2) carcinomas; Malignant Melanoma (2); synovial sarcoma (1), ampulla of Vater adenocarcinoma (1), pheochromocytoma (1), hypernephroma (1), and Hodgkin's Disease (1). The most common symptoms were dyspnea (80%), cough (66.6%) and hemoptysis (33.3%). Multiple (40%) or single (13.3%) pulmonary nodules, mediastinal or hilar lymphadenopathy (40%), and effusion (40%) were the most common radiographic findings. The mean interval from initial diagnosis to diagnosis of EBM was 32.8 months (range, 0-96 months) and median survival time was 18 months (range, 4-84). As a conclusion, various extrapulmonary tumors can metastasize to the bronchus. Symptoms and radiographic findings are similar with those in primary lung cancer. Therefore, EBM should be discriminated from primary lung cancer histopathologically. Although mean survival time is usually short, long-term survivors were reported. Consequently, treatment must be planned according to the histology of the primary tumor, evidence of metastasis to other sites and medical status of the patient.
 ...
PMID:Endobronchial metastases from extrathoracic malignancies. 1647 29

Pulmonary metastases of renal cell carcinoma are associated with poor prognosis. Systemic interleukin-2 is used to treat pulmonary metastases of renal cell carcinoma; however, its toxicity limits its use. The objective of this study was to evaluate the efficacy and safety of inhaled interleukin-2 in pulmonary metastases of renal cell carcinoma patients. The study was designed as a retrospective chart review in pulmonary metastases of renal cell carcinoma patients treated with inhaled interleukin-2. Between 2000 and 2004, 19 centres in Spain and two in Portugal recruited 51 patients. The treatment schedule was as follows: three cycles of 36 MIU interleukin-2 per day for 5 days/week for 12 weeks (with 1 treatment-free week between cycles) in Spain and for 3 weeks (out of each 4 weeks) for 12 weeks in Portugal. Efficacy was assessed by best response following each treatment cycle and at final evaluation. Kaplan-Meier method was used to estimate progression-free survival and overall survival. Safety data were analysed using descriptive statistics, with toxicities expressed in number of weeks, which were reported. Overall objective response rate was 13.7% (95% confidence interval: 5.7-26.3). Median progression-free survival and overall survival were 8.6 (95% confidence interval: 3.45-16.5) and 23 (95% confidence interval: 11.5-34.5) months. The most common toxicities were cough (40% of cycles) and fatigue (7%). The majority of weeks of toxicities were reported to be only grade 1 or 2 in severity. Inhaled interleukin-2 shows efficacy and mild toxicity of pulmonary metastases of renal cell carcinoma patients, and might be considered as an alternative treatment to the systemic administration of this drug in these patients.
 ...
PMID:Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. 1726 61

Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough.
 ...
PMID:Obstinate cough as a sole presenting symptom of non-metastatic renal cell carcinoma. 1776 Jul 55

A 46-year-old man had primary pulmonary symptoms of intermittent fever, cough and dyspnoea. Radiological investigations revealed a mass at right hilum with right upper lobe collapse. Bronchoscopy showed a luminal mass of which the biopsy showed a tumour with predominantly clear cell change. Subsequent investigations revealed primary renal adenocarcinoma. The differential diagnosis of clear cell lung tumour is discussed. This case of endobronchial metastasis from renal cell carcinoma is being presented because of its rarity.
 ...
PMID:Endobronchial metastasis from renal cell carcinoma: a case report. 1788 82

A 66-year-old man visited complaining of cough and sore throat. He had been exposed to asbestos 43 years ago. Chest X-ray revealed left pleural effusion and abnormal shadow in the right lung field. Chest computed tomography (CT) showed multiple enhanced nodules in the right pleural cavity. Abdominal CT showed a 3-cm enhanced tumor in the lower pole of the left kidney. Left radical nephrectomy was performed. Pathological diagnosis was renal cell carcinoma. Postoperatively pleural biopsy was performed by using thoracoscopy. White plaque was seen at the costal pleura and surface of lung. Pathological diagnosis was malignant pleural mesothelioma based on using mesothelium-associated antibodies: calretinin (+), CK5/6 (+), D2-40 (+), HBME-1 (+), TTF-1 (-), MOC31 (-), CEA (-). Combination therapy (extrapleural pneumonectomy, chemotherapy, and radiotherapy) was initiated. Malignant mesothelioma is a devastating neoplasm with a strong etiological relationship with asbestos exposure. The incidence is rising in industrialized countries, with the peak expected in the year 2020. However, renal cell carcinoma with malignant pleural mesothelioma is very rare and this is the 2nd case in the Japanese literature.
 ...
PMID:[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report]. 1805 6

We report a case of renal cell carcinoma in which interferon-a therapy was effective in reducing the tumor thrombus extending into the inferior vena cava. A 66-year-old man was referred to our hospital with a complaint of macroscopic hematuria, cough and general fatigue. We made a diagnosis of a left renal cell carcinoma with tumor thrombus by imaging examination. Because his performance status was 3, a radical operation was considered risky. Twenty-two months after the start of interferon-a therapy, the tumor thrombus was markedly reduced in size, and the clinical response was evaluated as partial response by the response criteria for urological cancer treatrment. Because of improvement of the performance status and downsizing of tumor thrombus, we performed radical nephrectomy. Pathological examinations revealed that viable renal cell carcinomas were found in the primary lesion and the tumor thrombus. In some cases, interferon-alpha therapy is useful and safe in the treatment of the tumor thrombus. Furthermore, radical nephrectomy and complete resection of the tumor thrombus prolongs postoperative survival.
 ...
PMID:[Successful preoperative interferon-alpha therapy of advanced renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report]. 1832 70

Cough is a common symptom in cancer. Its underlying cause should be managed when identified; otherwise, empiric treatment is the mainstay of symptom control. Cancer-related cough usually responds to radiation therapy, an opioid, or benzonatate, a peripheral anesthetic. We present the case of a patient with renal cell carcinoma hospitalized for intractable cough that failed to respond adequately to usual treatments, but improved with diazepam.
 ...
PMID:The cough from hell: diazepam for intractable cough in a patient with renal cell carcinoma. 1844 Jul 68

A 71-year-old female was referred with three right-sided intrathoracic tumours. In 2003, she underwent radical left nephrectomy for renal cell cancer (RCC) clinical stage 1. She was since followed at her local hospital with annual computed tomography (CT)-scans during the first five years and did not present any symptoms until October 2009 when she was admitted with shortness of breath, cough and tiredness. The patient was scheduled for a diagnostic thoracoscopy when it was discovered that her lesions were not located in the lung parenchyma but were protruding nodules from the parietal pleura. Histology demonstrated metastases from RCC which apparently can reach the parietal pleura without lung metastases.
 ...
PMID:Isolated pleural metastases from renal cell carcinoma. 2106 12

Sarcoidosis is a multi-systemic inflammatory disease of unknown origin characterized by the presence of noncaseating epitheloid cell granulomas in multiple organs. Diagnosis is made on the basis of a compatible clinical-radiological scenario and the histological demonstration of the typical granulomas in the affected tissues. Interferons are immuno-modulators that have been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and multiple myeloma and other types of tumours, including leukemia, lymphomas, Kaposi's sarcoma, and melanoma. Interferon-alpha-induced sarcoidosis has been reported repeatedly and there are two reports in the literature of cases of pulmonary sarcoidosis treated with interferon-1b therapy: one for advanced renal cell carcinoma and the other for multiple myeloma. A 35-year-old man on chronic immune-modulant Interferon-1b-based therapy for multiple sclerosis presented to the Neurology Unit with mild dyspnoea, dry cough, and transient pain to right upper abdomen. Lungs, spleen, liver, and almost all lymphnode stations of abdomen and mediastinum were clearly involved on ultrasound examination, chest X-ray, and computed tomography. A transbronchial biopsy showed non-caseating granuloma on histopathologic evaluation of the lungs. To the best of our knowledge, this is the first report of a chronic multisystemic sarcoidosis that was associated with interferon-beta treatment.
 ...
PMID:Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy. 2266 44


<< Previous 1 2 3 4 Next >>